Incyte Corp
NASDAQ:INCY
Intrinsic Value
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. [ Read More ]
The intrinsic value of one INCY stock under the Base Case scenario is 76.61 USD. Compared to the current market price of 52.35 USD, Incyte Corp is Undervalued by 32%.
Valuation Backtest
Incyte Corp
Run backtest to discover the historical profit from buying and selling INCY stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Incyte Corp
Current Assets | 4.6B |
Cash & Short-Term Investments | 4.1B |
Receivables | 743.6m |
Other Current Assets | -196.9m |
Non-Current Assets | 2.1B |
Long-Term Investments | 187.7m |
PP&E | 777m |
Intangibles | 279.1m |
Other Non-Current Assets | 892.8m |
Current Liabilities | 1.2B |
Accounts Payable | 1.5B |
Accrued Liabilities | 735.7m |
Other Current Liabilities | -952.6m |
Non-Current Liabilities | 351.9m |
Long-Term Debt | 29.2m |
Other Non-Current Liabilities | 322.7m |
Earnings Waterfall
Incyte Corp
Revenue
|
3.7B
USD
|
Cost of Revenue
|
-232.5m
USD
|
Gross Profit
|
3.5B
USD
|
Operating Expenses
|
-2.8B
USD
|
Operating Income
|
651.8m
USD
|
Other Expenses
|
-54.2m
USD
|
Net Income
|
597.6m
USD
|
Free Cash Flow Analysis
Incyte Corp
What is Free Cash Flow?
INCY Profitability Score
Profitability Due Diligence
Incyte Corp's profitability score is 64/100. The higher the profitability score, the more profitable the company is.
Score
Incyte Corp's profitability score is 64/100. The higher the profitability score, the more profitable the company is.
INCY Solvency Score
Solvency Due Diligence
Incyte Corp's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Score
Incyte Corp's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
INCY Price Targets Summary
Incyte Corp
According to Wall Street analysts, the average 1-year price target for INCY is 76.86 USD with a low forecast of 61.61 USD and a high forecast of 96.6 USD.
Ownership
INCY Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
INCY Price
Incyte Corp
Average Annual Return | 2.59% |
Standard Deviation of Annual Returns | 13.14% |
Max Drawdown | -52% |
Market Capitalization | 11.7B USD |
Shares Outstanding | 226 125 000 |
Percentage of Shares Shorted | 4.3% |
INCY News
Last Important Events
Incyte Corp
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Incyte Corp
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. The company is headquartered in Wilmington, Delaware and currently employs 2,094 full-time employees. The firm also conducts commercial and clinical development operations from its European headquarters in Morges, Switzerland and Japanese office in Tokyo. The company operates in two therapeutic areas, One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. The other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise is comprised of four products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib) and ICLUSIG (ponatinib), as well as other clinical development programs. Its Dermatology commercial franchise is comprised of OPZELURA (ruxolitinib) cream and other clinical development programs.
Contact
IPO
Employees
Officers
The intrinsic value of one INCY stock under the Base Case scenario is 76.61 USD.
Compared to the current market price of 52.35 USD, Incyte Corp is Undervalued by 32%.